BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen B, Wu JX, Cheng SH, Wang LM, Rong WQ, Wu F, Wang SL, Jin J, Liu YP, Song YW, Ren H, Fang H, Tang Y, Li N, Li YX, Wang WH. Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. Hepatology 2021;74:2595-604. [PMID: 34097307 DOI: 10.1002/hep.31993] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Su K, Guo L, Ma W, Wang J, Xie Y, Rao M, Zhang J, Li X, Wen L, Li B, Yang X, Song Y, Huang W, Chi H, Gu T, Xu K, Liu Y, Chen J, Wu Z, Jiang Y, Li H, Zeng H, Wang P, Feng X, Chen S, Yang B, Jin H, He K, Han Y. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. Front Immunol 2022;13:972503. [DOI: 10.3389/fimmu.2022.972503] [Reference Citation Analysis]
2 Zeng ZM, Mo N, Zeng J, Ma FC, Jiang YF, Huang HS, Liao XW, Zhu GZ, Ma J, Peng T. Advances in postoperative adjuvant therapy for primary liver cancer. World J Gastrointest Oncol 2022; 14(9): 1604-1621 [DOI: 10.4251/wjgo.v14.i9.1604] [Reference Citation Analysis]
3 Wang L, Qiu L, Ke Q, Ji H, Wu J. Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy. Radiother Oncol 2022:S0167-8140(22)04240-2. [PMID: 35998838 DOI: 10.1016/j.radonc.2022.08.019] [Reference Citation Analysis]
4 Wu QQ, Chen YX, Du SS, Hu Y, Yang P, Sun J, Wang XY, Wu WX, Zhang SM, Zeng ZC. Effect of the normal liver mean dose on intrahepatic recurrence in patients with hepatocellular carcinoma after receiving liver stereotactic body radiation therapy. Transl Oncol 2022;25:101492. [PMID: 35944415 DOI: 10.1016/j.tranon.2022.101492] [Reference Citation Analysis]
5 Wang H, Zhu X, Zhao Y, Dong D, Li L, Cai Y, Li Y, Wang W. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma. BMC Cancer 2022;22:771. [PMID: 35840914 DOI: 10.1186/s12885-022-09819-3] [Reference Citation Analysis]
6 Xu Y, Yang Y, Li L, Ye F, Zhao X. The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. Front Oncol 2022;12:905260. [PMID: 35686094 DOI: 10.3389/fonc.2022.905260] [Reference Citation Analysis]
7 Lu W, Hong W, Qiu H, Zhou Z, He Z, Zeng W, Zhong W, Xie J. A novel prognostic time window based on conditional survival and outcomes analyses of primary liver cancer patients. Cancer Med 2022. [PMID: 35460212 DOI: 10.1002/cam4.4762] [Reference Citation Analysis]
8 Wang Y, Chen H, Liu Y, Xiao H, Wang X, Zhong Z, Gao P, Zhang Z, She J, Liu J, Huang L, Jiang H. Treatment optimization for recurrent hepatoblastoma: retrospective study from a hepatoblastoma cohort in Southern China. Pediatr Surg Int. [DOI: 10.1007/s00383-022-05126-x] [Reference Citation Analysis]
9 Zhang XP, Chen XJ, Li BZ, Xu S, Wu ZL, Hu MG, Zhao ZM, Zhao GD, Wang CR, Hong W, Li SP, Li L, Wang CG, Nie G, Liu R. Active targeted Janus nanoparticles enable anti-angiogenic drug combining chemotherapy agent to prevent postoperative hepatocellular carcinoma recurrence. Biomaterials 2022;281:121362. [PMID: 34998170 DOI: 10.1016/j.biomaterials.2022.121362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]